Skip survey header

2017 Clinical Conference Evaluation & Post Test - Enduring Materials Format: Cancer Genetics Part 2


May 23, 2017- Evaluation - Genetics & CA Pt 2- Presented by; Margo Thelander, MS, CGC
Estimated Time to complete the activity is 45 minutes. Activity and content expires: 05-23-2020
Statement of disclosure: The planners and faculty for this activity have no relevant financial relationships with commercial interests. No others individuals involved in the planning or presentation of this activity have any relevant financial relationships with commercial interests to disclose.
Accreditation Statement: John Muir Health is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians.
Credit Designation Statement: John Muir Health designates this enduring material for a maximum of one (.75) AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
Minimum level of achievement:   Must score 75% correct on posttest and complete the statement of how you will improve your practice after participation is mandatory.
JMH Internet Policy:
1. Physician Info
2. Member ABIM
This question requires a valid date format of MM/DD/YYYY.
4. As a result of attending this CME activity, which of these do you plan to implement and/or change in your practice? *This question is required.
Space Cell DefinitelyMaybeNo Change
Differentiate between older and newer treatment options.
Formulate and communicate treatment plans for the management of medically and socially complex patients
Apply best practice strategies to overcome co-morbidities in medically and socially complex patients
Utilize EBM Guidelines for a multitude of conditions that are encountered in primary care
Apply tips and tricks for navigating Epic.
Utilize Patient Centered Care skill to help patients become better informed and more involved in their health care decisions
8. The session’s content matched my scope of care
9. The presentation was unbiased.
10. Ample time was provided for discussion and interaction with the speaker(s.)
11. Your patient is a 45-year-old woman whose mother and maternal grandmother both had breast cancer diagnosed under age 50; and there is no breast cancer on the paternal side of her family. Your patient tested negative for mutations in the BRCA1 and BRCA2 genes two years ago. How would you assess her risk of developing breast cancer? ​
Select all that apply
12. For the above patient, would her risk of developing breast cancer be more accurately assessed by performing further genetic testing on her mother (assuming she’s still living) or herself?
Select all that apply
13. If further genetic testing in the above patient and her mother does not find a genetic cause for the breast cancers in the family, how would you determine the appropriate breast cancer screening for your unaffected 45-year-old patient? 
Select all that apply
14. If your patient has a diagnosis of colon cancer and his/her surgical pathology report indicates that one or more mismatch repair proteins are absent in the tumor cells, this indicates that your patient has an inherited mutation in one of the mismatch repair genes, and he/she should follow the NCCN Guidelines for Management of Patients with Lynch Syndrome.